## **Core Concept**
Tumor Lysis Syndrome (TLS) is a life-threatening complication that occurs when a large number of cancer cells die rapidly, releasing their contents into the bloodstream. This leads to several metabolic abnormalities, including hyperuricemia, hyperphosphatemia, hypocalcemia, and hyperkalemia.

## **Why the Correct Answer is Right**
The correct answer, , is associated with Tumor Lysis Syndrome because TLS leads to the release of intracellular contents from lysed cancer cells. This includes nucleic acids, which are catabolized to uric acid, leading to **hyperuricemia**. Additionally, cancer cells contain high levels of phosphate, which is released into the bloodstream, causing **hyperphosphatemia**. The high phosphate levels can bind to calcium, leading to **hypocalcemia**. Lastly, cancer cells also contain high levels of potassium, which is released into the bloodstream, causing **hyperkalemia**.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Hyperuricemia is a hallmark of TLS due to the breakdown of nucleic acids from lysed tumor cells.
- **Option B:** Hyperphosphatemia occurs due to the release of phosphate from lysed tumor cells.
- **Option D:** Hyperkalemia is seen in TLS due to the release of potassium from lysed tumor cells.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that TLS is most commonly associated with **chemotherapy** for cancers with a high cell turnover, such as acute leukemias and lymphomas. Early recognition and management of TLS, including hydration, diuresis, and use of medications like allopurinol or rasburicase to manage hyperuricemia, are critical.

**Correct Answer:** . Hypocalcemia